ReachMD CME

ReachMD
  • ٤٫٣ (٣)
  • العلوم

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

  1. ٢٣ يونيو

    Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF

    CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice. =

    ١٧ د

  2. ١٦ يونيو

    Unblocking Clinical Inertia: The CMI Era in oHCM Care

    CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It’s not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart failure and how cardiac myosin inhibitors can optimize patient outcomes. Join us and gain valuable tips on applying these insights in practice. For more information please visit the Heart Failure Congress 2026 website. =

    ٣٩ د

  3. ١٥ مايو

    IBD in Focus: A Case-Based Approach to Diagnosis and Assessment

    CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/ibd-in-focus-a-case-based-approach-to-diagnosis-and-assessment/49150/ In this case-based discussion, Drs. Dolinger and Rubin examine the diagnostic approach to patients presenting with signs and symptoms suggestive of inflammatory bowel disease (IBD). The conversation explores key steps in the initial evaluation, appropriate laboratory testing, the role of colonoscopy versus additional noninvasive work-up, and how imaging modalities such as intestinal ultrasound contribute to disease characterization. The faculty also address methods to assess disease severity and activity, incorporating clinical indices, endoscopic findings, and risk stratification. =

    ١٩ د

  4. ١٥ مايو

    Movements With Meaning: Reading the Pattern, Not the Label

    CME credits: 0.25 Valid until: 15-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/movements-with-meaning-reading-the-pattern-not-the-label/54715/ This Podcast Plus discussion examines how to distinguish tardive dyskinesia (TD) from other movement disorders using clinical features, medication timing, and response patterns. Key characteristics of TD, including irregular orofacial movements, are compared with drug-induced parkinsonism and akathisia. The discussion highlights the delayed onset of TD following dopamine receptor-blocking agents and compares timing across movement syndromes. It also emphasizes why TD should not be grouped with other extrapyramidal symptoms, as it may be missed, masked, or coexist with other conditions, affecting treatment decisions. =

    ١٣ د

  5. ١٤ مايو

    Closing the Gap: Equity, Disparities, and Access to TD Diagnosis and Care

    CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-equity-disparities-and-access-to-td-diagnosis-and-care/56644/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

    ٥ د

  6. ١٤ مايو

    From “EPS” to Personalized TD Treatment: Matching VMAT2 MOA to the Patient

    CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-eps-to-personalized-td-treatment-matching-vmat2-moa-to-the-patient/56646/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

    ٥ د

  7. ١٤ مايو

    Not All VMAT2s Are the Same: Understanding the PK/PD Differences

    CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/not-all-vmat2s-are-the-same-understanding-the-pkpd-differences/56645/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

    ٥ د

  8. ١٤ مايو

    Shared Decisions, Real Patients: Patient-Centered TD and Antipsychotic Strategies

    CME credits: 1.00 Valid until: 26-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/shared-decisions-real-patients-patient-centered-td-and-antipsychotic-strategies/56648/ Tardive dyskinesia (TD) remains significantly underdiagnosed and mismanaged despite clear guidelines. Early symptoms are often misattributed and standardized assessment tools go unused, leading to delayed detection and treatment. This ultimately contributes to substantial patient burden and is worsened by inequities in access to care, particularly among high-risk and underserved populations. Although VMAT2 inhibitors are recommended as first-line treatments, clinicians need practical guidance on individualized selection and use in complex cases. This series addresses these challenges by emphasizing standardized screening, improved diagnostic differentiation, more equitable care pathways, and evidence-based, patient-centered treatment strategies. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

    ٤ د
مشاهدة الكل (٤١٤)

التقييمات والمراجعات

٤٫٣
من ٥
‫٣ من التقييمات‬

حول

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

المعلومات

  • صناع العمل
    ReachMD
  • سنوات النشاط
    ٢٠١٥ - ٢٠٢٦
  • الحلقات
    ٤١٤
  • التقييم
    ملائم
  • حقوق النشر
    © Copyright 2026 ReachMD. All rights reserved.
  • موقع البرنامج على الويب
    ReachMD CME